Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2646
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    47,931.20
    -11.22 (-0.02%)
     

  • CMC Crypto 200

    1,261.45
    -22.37 (-1.74%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand

Vandana Singh
·2-min read
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand

Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply.

China’s National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.

Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows.

Maziar Mike Doustdar, Novo Nordisk’s chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere.

ADVERTISEMENT

China’s health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk’s diabetes drug, Ozempic, has been used off-label to shed weight.

As urbanization drives obesity rates, China’s market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030, Bloomberg notes, citing HSBC analysis.

However, Novo Nordisk’s patent on semaglutide, Wegovy’s active ingredient, expires in 2026, with Hangzhou Jiuyuan Gene Engineering Co. and Livzon Pharmaceutical Group Inc. already seeking to produce generic versions.

Eli Lilly And Co (NYSE:LLY) is also a key competitor, with its obesity drug under review in China. Lilly and Innovent Biologics Inc. are also developing a local weight-loss drug that is expected to launch next year.

Bloomberg report adds that Novo Nordisk has struggled to meet global demand for Wegovy and Ozempic, but it continues to manufacture semaglutide in Denmark and North Carolina and is planning final production stages in China.

A 4 billion yuan factory expansion in Tianjin was announced in March.

While China’s national health insurance covers Ozempic for diabetes, Wegovy is unlikely to receive similar reimbursement.

As a result, Wegovy will likely target those able to pay out-of-pocket, allowing Novo Nordisk to set prices independently.

Currently, Ozempic is available on major Chinese platforms like JD.com Inc (NASDAQ:JD) and Alibaba Group Holding Ltd.’s (NYSE:BABA) Tmall.

Price Action: NVO shares are down 0.10% at $143.52 at last check Thursday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo by Tobias Arhelger via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.